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Increasing evidence suggests a detrimental effect of donor-
specific antibodies directed against the human leukocyte
antigen (HLA)-A, -B, and -DR loci on renal allograft outcomes.
Limited data exist on the impact of de novo HLA-DQ
antibodies. Over a 3-year period, we prospectively
monitored 347 renal transplant recipients without pre-
transplant donor-specific antibodies for their development
de novo. After 26 months of follow-up, 62 patients
developed donor-specific antibodies, of which 48 had
a HLA-DQ antibody either alone (33 patients) or in
combination with an HLA-A, -B, or -DR antibody (15
patients). Only 14 patients developed a donor-specific HLA-
A, -B, or -DR antibody without a HLA-DQ antibody present.
Acute rejection occurred in 21% of the HLA-DQ–only
patients, insignificant when compared with 11% of patients
without donor-specific antibodies. At the last follow-up, the
mean serum creatinine and the fraction of patients with
proteinuria were significantly higher in those that developed
only HLA-DQ than those without antibodies. The 3-year graft
survival was significantly worse when HLA-DQ antibodies
were combined with non-DQ antibodies (52%) compared
with HLA-DQ alone, non-DQ antibodies alone, or no
antibodies (92–94%). Thus, our prospective monitoring study
found that donor-specific HLA-DQ antibodies were the most
common type detected and these antibodies may contribute
to inferior graft outcomes. Ongoing surveillance is necessary
to determine the long-term outcome of patients developing
HLA-DQ donor-specific antibodies.
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An increasingly popular area of research in renal transplanta-
tion is the contribution of the humoral immune system to
post-transplant outcomes. In recent years, there has been
much debate regarding the role and significance of de nosvo
donor-specific antibody (DSA) development after renal
transplantation. Several reports show an association between
donor human leukocyte antigen (HLA)–specific antibodies
and inferior graft outcomes, including decreased renal
function, increased incidence of acute antibody–mediated
rejection (AMR),1–3 and a higher rate of allograft failure.1,4–6
Allograft loss following development of DSA may be a result of
a higher frequency of chronic AMR and transplant glomer-
ulopathy.3,7–10 Controversy still exists as to whether the inferior
outcomes associated with DSA occur independently or as a
result of injury caused by acute rejections (ARs) incurred
during DSA exposure. Regardless, recent evidence seems to
favor a detrimental effect of DSA on long-term outcomes.
Over the past decade, new and more sensitive methods of
antibody and antigen detection have become commercially
available. These have afforded the opportunity to more
accurately detect specific antibodies, including those of the
DQ locus. The current UNOS organ allocation system, which
historically placed an emphasis on HLA-A and -B, has more
recently awarded points for matching at the HLA-DR
antigen, and does not take into consideration HLA-DQ
matching. Minimal evidence exists regarding the impact of
DQ mismatch on the rate of DQ DSA development and
allograft outcomes, issues that remain controversial.
Through the use of routine post-transplant DSA monitor-
ing, we have noticed a predominance of class II DSA after
renal transplantation, specifically those directed against DQ
antigens. This observation is consistent with the current
literature; nonetheless, few studies report on the specific
incidence of DQ DSA.3,10,11 While it has generally been
accepted that DSA directed toward HLA-A, -B, and -DR loci
are clinically relevant, limited data exist regarding the clinical
significance of DSA directed against the DQ antigen. Thus,
the purpose of our study was to report the incidence and
impact of de novo donor–specific DQ antibodies on outcomes
following renal transplantation.
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RESULTS
Patient selection
We reviewed 389 consecutive kidney and combined kidney–-
pancreas transplants from July 2007 to July 2010. A total of
37 patients were excluded owing to pre-transplant DSA and/
or the need for desensitization therapies. In addition, four
patients who lost their graft within the first post-operative
month and one patient who transferred care within the first
month were also excluded from the analysis. Patient
disposition is shown in Figure 1. Of the 347 remaining
patients, the majority were male (60%), Caucasian (43%),
and received deceased donor transplants (61%). About 25
patients (7%) received a simultaneous pancreas–kidney
transplant. Median follow-up was 26 months (range, 3–47).
Baseline characteristics are shown in Table 1.
Immunosuppressive therapy
Table 1 lists antibody induction use by group. All but three
patients, who were enrolled in a study prohibiting antibody
induction, received either antithymocyte globulin (ATG) or
interleukin-2 receptor antagonists. Most (60%) patients
received ATG induction as a primary induction agent per
protocol, while only eight patients (2%) were converted from
interleukin-2 receptor antagonists to ATG for delayed graft
function. The mean dose of ATG for the entire cohort was
4.97±1.2mg/kg, with no differences seen between groups.
Only 12% of patients were tapered off of steroids before
discharge, with no differences in the use of steroid with-
drawal being noted among groups. Similarly, tacrolimus
trough concentrations, mean prednisone doses, and mean
mycophenolate mofetil doses were similar across groups
(Supplementary Table S1 online).
De novo DSA
Sixty-two (18%) of the 347 patients developed at least one de
novo post-transplant DSA. As shown in Figure 1, 33 (10%)
patients had DQ DSA alone (DQ-only), 14 (4%) patients
developed a donor-specific -A,-B, and/or -DR antibody
without a DQ antibody present (nonDQ), and 15 (4%)
patients developed a DQ antibody in addition to other non-
DQ antibodies (DQþ nonDQ). Thus, 48 (77%) patients had
a DQ antibody making it the most prevalent DSA detected.
The most common of the DQ antibodies found were DQ7
(25%), DQ2 (19%), and DQ4 (19%). The mean number of
DSA samples attained per patient was 6±3.
HLA mismatch and PRA
None of the zero-mismatched patients developed de novo
DSA and there were no differences in the degree of HLA-A,-
B, and –DR matching among any of the groups with DSA
(Table 1). There was a greater number of DQ mismatches in
the DQ-only (1.3±0.6) group compared with the no-DSA
group (0.9±0.7; P¼ 0.003). There was no difference in mean
peak pre-transplant panel reactive antibody (PRA) or the
number of very highly sensitized patients (peak PRA480%)
among the groups (Table 1).
Timing and strength of DSA
DSA detection occurred at a median of 6.1 months (range,
0.4–44) and a mean of 8.1±8.8 post transplant (Figure 2). In
the DQ-only group, 75% (24/33) of DSA occurred within
6 months of transplant. While there was a tendency for later
detection of DSA in the DQþ nonDQ group, there was no
statistical difference in mean time to DSA development among
groups (7.2±11.6 months for DQ-only, 6.5±7.4 months for
nonDQ, and 11.9±7.8 months for DQþ nonDQ; P¼ 0.17).
Recipients in the DQþ nonDQ group were more likely to
have persistent DSA (DSA present at more than one time
point) compared with those in both the DQ-only and nonDQ
groups (87% vs. 45% and 43%, respectively, P¼ 0.01).
Strength of the peak DSA in each group is shown in
Figure 3a. There were significantly more weak and moderate
DSA and fewer strong DSA in the DQ-only group when
compared with the DQþ nonDQ group (P¼ 0.001) and no
difference between DQ-only and nonDQ groups.
Acute rejection
DSAs were detected at a median of 4 days (range, 229–195)
and mean of 2.3±82 days following an AR diagnosis, with no
differences observed between groups (Table 2). The overall
incidence of biopsy-proven AR during the follow-up period
was 15% (52/347), with a higher rate in the nonDQ and
DQþ nonDQ groups compared with the no-DSA group.
Although not statistically higher, the incidence of AR in DQ-
only patients was double that of the no DSA group (21% in
DQ-only vs. 11% in no DSA; P¼ 0.11).
As would be expected, there was a higher rate of AMR in
the DQ-only group, while the highest incidence was seen in
DQþ nonDQ patients (60%). Importantly, five patients
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Figure 1 |Patient selection. DSA, donor-specific antibody.
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in the DQþ nonDQ group were noncompliant before AMR
diagnosis and a sixth patient was started on an anti-tremor
medication as an outpatient resulting in undetectable
tacrolimus concentrations. In order to determine if there
was a relationship between DSA strength and AMR, we
reviewed peak median fluorescence indexes (MFIs) in the DQ-
only group. We observed that patients with moderate and
higher (44000 MFI) DSA had a trend toward more AMR (3/
19) compared with those with a weak DSA (0/14; P¼ 0.06), as
well as more graft loss (2/19 vs. 0/14, respectively; P¼ 0.13).
Renal function
Renal function as demonstrated by serum creatinine and
degree of proteinuria is shown in Table 2. Only patients with
nonDQ antibodies exhibited higher creatinines early post
transplant (6 months); however, at most recent follow-up, all
patients with DSA, regardless of type, had significantly higher
creatinines than no DSA patients (Po0.001). Even in
patients with DQ DSA-only, the most recent serum creatinine
was significantly higher than patients without DSA (1.6 vs.
1.3mg/dl, respectively; P¼ 0.02). The degree of proteinuria
was assessed by a spot urine protein-to-creatinine ratio and
considered clinically significant when greater than 0.5. Again,
an early difference was seen in the nonDQ group; however, by
most recent follow-up, patients in both DQ-only and
DQþ nonDQ groups demonstrated a higher rate of protei-
nuria compared with the no DSA group.
Graft and patient survival
For the entire cohort, uncensored graft survival, death-
censored graft survival, and patient survival at 3 years post
transplant were 92, 96, and 94%, respectively. Uncensored
graft survival was significantly worse in the DQþ nonDQ
group (52%) compared with all other groups (92–94%;
Table 1 | Baseline characteristics of patients according to DSA group
No DSA DQ only NonDQ DQ+NonDQ P-value
Total number of patients, n (%) 285 (82) 33 (10) 14 (4) 15 (4)
Recipient
Gender—male, n (%) 169 (59) 22 (67) 7 (58) 10 (59) 0.87
Age at transplant, mean±s.d. 49±14 50±13 48±19 45±14 0.74
Ethnicity
Caucasian, n (%) 131 (46) 9 (27) 3 (21) 6 (40) 0.06a
African American, n (%) 66 (23) 12 (36) 7 (50) 6 (33) 0.08
Hispanic, n (%) 71 (25) 8 (24) 2 (21) 4 (27) 0.99
Retransplant, n (%) 24 (8) 0 1 (7) 1 (7) 0.14a
Mean HLA mismatch/6, mean±s.d. 3.6±1.8 4.1±1.3 4.6±1.2 4.7±1.1 0.01b,c
Mean DQ mismatch/2, mean±s.d. 0.9±0.7 1.3±0.6 1.4±0.6 1.1±0.6 0.06a,b
PRA, mean±s.d. 18±30 15±27 23±32 15±25 0.81
Peak PRA480%, n (%) 30 (11) 2 (6) 1 (3) 0 (0) 0.27
Donor
Gender – male, n (%) 144 (53) 14 (44) 9 (64) 8 (57) 0.59
Age, mean±s.d. 39±16 37±16 40±17 41±15 0.86
Deceased donor, n (%) 168 (59) 23 (70) 9 (75) 12 (71) 0.36
Induction therapy
IL2RA, n (%) 119 (42) 9 (27) 2 (14) 6 (40) 0.07b
ATG, n (%) 164 (58) 23 (70) 12 (86) 8 (53) 0.08b
Outcomes
Delayed graft function, n (%) 25 (9) 2 (6) 3 (21) 1 (7) 0.49
Abbreviations: ATG, human antithymocyte globulin; DSA, donor-specific antibody; HLA, human leukocyte antigen; IL2RA, interleukin 2 receptor antagonist (i.e., basiliximab
and daclizumab); PRA, panel reactive antibody.
aPo0.05 for no DSA vs. DQ only.
bPo0.05 for no DSA vs. nonDQ.











Follow-up after 26 months was not complete. 
Of the 189 patients with follow-up past 24 months, only 3
developed de novo DSA at 27, 30, and 42 months post transplant.
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Figure 2 |Time to DSA development post transplant. DSA,
donor-specific antibody.
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P¼ 0.0004). However, there was no difference in graft
survival between the remaining three groups. Excluding
patient death, nine graft losses occurred in the cohort. As
shown in Table 3, there were no differences in causes of graft
loss between the groups. Of the patients with DSA, all graft
losses occurred in patients with MFI in the moderate, strong,
or very strong range with none occurring in those with weak
DSA (Figure 3b).
DISCUSSION
Increasing evidence highlights the significant impact of DSA
against HLA -A, -B, and -DR antigens in kidney transplanta-
tion; however, the importance of DQ DSA alone is not well
described. Similar to other reports, we have noticed a
predominance of DQ DSA through the use of routine post-
transplant monitoring. Our results suggest that DQ anti-
bodies are the most common de novo DSA detected post
transplant, and that these antibodies may be associated with a
detrimental effect in terms of rejection and graft dysfunction.
Furthermore, while we observed no difference in graft
survival in patients with DQ antibodies alone, DQ antibodies
detected in conjunction with other class I and class II
antibodies were associated with significantly reduced graft
survival. Importantly, AMR and graft losses did not occur in
patients with low levels of DQ-only antibodies.
Here, we report an overall prevalence of de novo DSA of
18%, while the rate reported in the literature is highly variable
ranging from 4 to 27%.2,4,11,12 In studies that prospectively
monitor for de novo DSA, this prevalence appears to
consistently range from 22–27%.2,4,7 Until recently, most
studies reporting on the impact of class II antibodies focus














Peak DSA strength for each patient—weak = 2000–4000 MFI; 
moderate = >4000–8000 MFI; strong = >8000–15,000 MFI; very strong = > 15,000 MFI.
P -value < 0.05 for creatinine comparing weak vs. very strong; 
moderate vs. very strong; strong vs. very strong and weak vs. strong
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Figure 3 |Mean fluorescence index and outcomes.
(a) Fluorescence index of DSA according to group. (b) Clinical
outcomes based on MFI. DSA, donor-specific antibody; MFI,
median fluorescence index.
Table 2 | Rejection and renal function
No DSA DQ only NonDQ DQ+nonDQ P-value
Total number of patients, n (%) 285 (82) 33 (10) 14 (4) 15 (4)
Acute rejection (AR), n (%) 31 (11) 7 (21) 4 (29) 10 (67) o0.001c,d,f
Antibody-mediated rejection (AMR), n (%) 1/285 (0.4)* 3/33 (9) 1/14 (7) 9/15 (60) o0.001a,c,d,f
Time from AR to DSA detection — 4±100 10±33 5±87 0.95
Serum creatinine (mg/dl)
6 months after transplant 1.3±0.4 (n=236) 1.3±0.1 (n=29) 1.8±0.2 (n=12) 1.3±0.2 (n=13) 0.09b,e
Most recent (end of study) 1.3±0.6 (n=250) 1.6±0.8 (n=33) 1.7±0.9 (n=14) 2.6±1.2 (n=14) o0.001a,b,c,d,f
Spot urine protein/creatinine ratio 40.5, n (%)**
6 months after transplant 15/195 (8) 5/24 (21) 3/10 (30) 3/12 (25) 0.03b
Most recent (end of study) 23/251 (9) 7/29 (24) 2/13 (15) 4/13 (31) 0.03a,c
Abbreviation: DSA, donor-specific antibody.
*Renal transplant biopsy showed presence of capillaritis, polymorphonuclear leukocytes (PMNs), and positive C4d staining in450% of the peritubular capillaries suggestive
of AMR despite the lack of DSA in serum.
**Not all recipients had urine protein/creatinine ratio available; thus, the total number of patients is different than that of the entire group.
a Po0.05 for no DSA vs. DQ only.
b Po0.05 for no DSA vs. nonDQ.
c Po0.05 for no DSA vs. DQ+nonDQ.
d Po0.05 for DQ only vs. DQ+nonDQ.
e Po0.05 for DQ only vs. nonDQ.
f Po0.05 for nonDQ vs. DQ+nonDQ.
Table 3 | Causes of graft loss by DSA group (excluding death)
No DSA (n=3) BKN, CAN, unknown
DQ only (n=1) Rejection
NonDQ (n=1) BKN
DQ+nonDQ (n=4) BKN, rejection (2), unknown
Abbreviations: BKN, BK nephropathy; CAN, chronic allograft nephropathy.
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primarily on outcomes related to DR. Through the use of solid
phase antibody detection and identification methods, improved
reporting and better characterization of HLA-directed anti-
bodies, including DQ antibodies, have been attained before and
after transplant. Of the studies published that report the
percentage of de novo DSA directed against DQ, the rate
reported varies from 33 to 90%.11,13,14 This variation may be
attributed to differences in sample collection times, assays used
to detect antibodies, and the MFI cutoff considered significant.
In the cohort of patients reported herein, 77% developed a DQ
DSA. The reason for the high rate of DQ DSA remains
unknown, even recent data indicate that HLA-DR mismatches
may be more immunogenic than DQ. This may be in part due
to the fact that DR, but not DQ, matching is taken into
consideration in the current UNOS allocation system.
In this report, we found that the majority of DSA occur
within 6 months post transplant, with no difference in time
to DSA development between all groups. Using a similar
routine prospective DSA monitoring protocol, Cooper et al.
found that 91% of DSA were detected within 6 months of
transplant, while Zhang et al. reported that 63% of patients
developed DSA within 1 month after transplant with the
remaining 37% developing within 6 months post trans-
plant.2,4 We did notice a slight delay in detection in the
DQþ nonDQ DSA group, with a median time of detection
around 11 months compared with the other groups at 6
months. This may be the result of a higher rate of detection
‘for cause’ as opposed to predetermined screening time
points, specifically for episodes of graft dysfunction. Conse-
quently, this group had a higher rate of AMR, in many cases
as a result of noncompliance.
We found an increased incidence of AR in each of the DSA
groups compared with the no DSA group. The rate of AR in
the DQ-only patients compared with the no DSA patients
was approximately double. The difference lacked statistical
significance, likely a result of the small sample size; however,
the trend may be clinically relevant. In contrast to an earlier
report, the incidence of AMR in the DQ-only group was
significantly higher than in the no DSA group.13 Further-
more, recent data indicate that DQ antibodies are common
during periods of AMR and is suggestive of the DQ antigen
being upregulated by cells as part of an inflammatory
response.15 Controversy exists with regards to whether
inferior renal outcomes are due to de novo DSA themselves
or to previous rejection episodes in patients with DSA.4 In
the current study, while we noted an increased incidence of
AR in the DQ group, we did not find a difference in graft
survival at 3 years when including patients with AR possibly
due to the relatively short-term follow-up in our cohort, or
to possible interventions made soon after DSA detection.
However, patients expressing DQ antibodies in conjunction
with HLA-A, -B, or -DR antibodies did show inferior graft
survival suggesting a cumulative effect of the number, types,
and strength of antibodies present. Overall, we feel that
even in the absence of AR, the presence of de novo DSA
likely represents a proportion of patients who are generally
under-immunosuppressed and are thus at risk for subsequent
acute or chronic rejection. This is supported by studies
demonstrating an independent effect of DSA on allograft
survival3,8,16–18 and several studies demonstrating the pre-
sence of DSA, including DQ antibodies in grafts lost owing to
chronic rejection.3,19 All graft losses and AMRs in the DQ-
only group occurred in patients with an MFI of at least 4000,
similar to the results by Everly et al.1 showing that in patients
with AMR and DSA, those with higher DSA MFI’s had worse
outcomes, and of all patients with AMR and DSA only 4 of 22
(18%) had DSAo5000 MFI.
Our study also supports previous reports of worse renal
function in recipients with DSA compared with those
without.3,8,20–23 Moreover, DQ-only patients exhibited similar
renal function to those with other types of DSA and higher
creatinines compared with those without DSA, suggesting that
DQ DSA may have as much of an impact on graft function as
DSA directed against –A, –B, and –DR antigens.
There are several limitations of our study. Our definition
of de novo DSA included those previously unrecognized
before transplant at any MFI, but present post transplant at
an MFI greater than 2000. We recognize that our MFI cutoff
of 2000 is higher than other published studies, which range
from 500 to 1000.1,4,10 However, it is certainly possible that
both before and after transplant these antibodies may have
been below the detection limits of Luminex/LabScreen
system or reflect a memory cell response to previous
challenge by the cognate antigen. There is not currently a
universally accepted MFI cutoff, and we felt that a cutoff of
2000 MFI was clinically relevant in our patients as it
approximated the level at which a B-cell flow crossmatch
becomes positive and below 2000 MFI the sound to noise
ratio is not high enough to ensure that there are actually
DSA and not background noise. Perhaps, the higher cutoff
value could have contributed to an underestimation of the
true incidence of de novo DSA, and additionally, the impact
of low-titer DSA was unable to be determined. Our current
follow-up of 26 months is relatively short and despite having
seen a nonsignificant trend toward higher AR and signifi-
cantly worse renal function, further monitoring is warranted
to determine whether graft survival in the DQ-only group
remains equivocal to patients without DSA. The retro-
spective nature of our study carries the inherent limitations
that any retrospective study would, such as variability of reporting,
era bias, nonstandard follow-up time and intervals, and
missing data. Because of this study’s retrospective and des-
criptive nature, a power analysis was not performed that may
have resulted in the nonstatistical difference in AR between
DQ and no DSA groups being due to a type II error.
Overall, our data suggest that development of de novo DQ
DSA, of which the significance has historically been
unknown, may have clinically relevant implications. With
an understanding of the significance of de novo DSA, future
efforts to determine potential mechanisms to remove these
and other antibodies in order to decrease the risk of acute
and chronic rejection should be prioritized. Research of
602 Kidney International (2012) 82, 598–604
or ig ina l a r t i c l e JM DeVos et al.: Impact of donor-specific DQ antibodies after renal transplantation
investigational therapies such as intravenous (IV) immune
globulin, plasma exchange, and/or depleting antibodies, such
as rituximab, are imperative to determine their ability to
remove DSA and potentially alleviate long-term conse-
quences of all classes of DSA, including DQ. It may also be
beneficial to determine whether or not DQ antibodies are
complement fixing in the context of AMR, implying that they
are capable of forming a membrane attach complex leading
to cell destruction in situ.
In conclusion, through prospectively monitoring DSA, we
detected a high rate of de novo DQ DSA. DQ antibodies
individually, particularly those expressed at higher MFIs,
resulted in graft outcomes that were inferior compared with
patients without DSA, and similar to those seen with more
established de novo HLA antibodies. These data suggest patients
with antibodies to DQ may require similar interventions as
those with de novo -A, -B, and -DR antibodies. Ongoing
surveillance of clinical outcomes in this patient population is
necessary to determine the long-term impact of DQ DSA.
MATERIALS AND METHODS
Patients
This was a single-center, retrospective review of adult (X18 years old)
living and deceased donor kidney and kidney/pancreas recipients
transplanted between July 2007 and July 2010. Patients with DSA in
historical sera before transplant at any detectable mean fluorescence
index (MFI) and/or requiring desensitization (i.e., anti-CD20
antibody, IV immune globulins, or plasmapheresis) were excluded
from the analysis. Patients who lost their graft or were lost to follow-
up before the first post-operative month were also excluded.
Retrospective analyses were approved by The Methodist Hospital
Institutional Review Board.
Immunosuppression protocol
Patients with a PRA score greater than 20%, African Americans,
kidney/pancreas recipients, and those developing delayed graft
function received IV rabbit ATG 1.5mg/kg for a total of 3–5 doses.
All remaining patients received interleukin-2 receptor antagonist
induction with either daclizumab 2mg/kg IV or basiliximab 20mg
IV on post-operative days 0 and 4. Maintenance immunosuppres-
sion consisted of tacrolimus, mycophenolate, and corticosteroids.
Tacrolimus was initiated following a drop in creatinine by B30%
from baseline and adjusted to maintain trough levels of 6–12 ng/ml
during the first year and 4–8 thereafter. Mycophenolate mofetil was
given in divided doses to achieve a goal dose of 2 g/day. Patients
received IV methylprednisolone 200mg intraoperatively, which was
tapered post-operatively to a maintenance dose of 5–10mg daily by
2–3 months post transplant.
Determination of post-transplant DSA
Recipient sera was screened for class I and class II HLA DSA through
the use of single HLA antigen-charged polystyrene beads according
to the manufacturer’s instructions (LABScreen; One Lambda,
Canoga Park, CA) utilizing a multichannel flow array (Luminex,
Austin, TX), and identified via Fusion software (LABScreen; One
Lambda). There were not a minimum number of beads per
specificity to identify antibodies nor were allelic DSAs detected. Per
protocol, patient serum was prospectively monitored for DSA at
months 1, 3, 6, 9, and 12 post transplant, every 6 months thereafter,
and during episodes of graft dysfunction or rejection. A positive
de novo DSA was defined as a new antibody not present before
transplant with donor specificity and a MFI of greater than 2000,
which is at the lowest limit of detection by a flow cytometric
crossmatch in our center. For both pre-transplant and post-
transplant DSA, only those at an MFI greater than 2000 were
considered because in our hands the signal to noise ratio below 2000
MFI is not high enough that we can confidently say they are actually
donor-specific antibodies and not background noise.
Strength of DSA were defined as the following; weak 2000–4000
MFI, moderate 44000–8000 MFI, strong 48000–15,000 MFI,
and very strong 415,000 MFI. In our system, 4000 MFI is the
approximate lower limit of a positive B-cell flow crossmatch, while
8000 and greater MFI antibodies are associated with increasingly
positive AHG cytotoxic crossmatches. Peak-MFI DSA was defined as
the highest MFI of a single DSA in each individual recipient.
HLA typing methods
Donor and recipient typings were done by molecular methods
according to their respective manufacturers directions. All recipients
and living donors were typed by a flow bead array using sequence-
specific oligonucleotide probes (Labtype SSO, One Lambda) with
positive hybridization detected by Luminex and data analyzed by
Fusion software (One Lambda). All deceased donors were typed via
sequence-specific primers (HLA-A/B/DR/DQ-SSP UniTray, Life
Technologies/Invitrogen, Carlsbad, CA), results obtained by 2%
agarose/ethidium bromide gel electrophoresis, and data analyzed by
vendor supplied software.
Diagnosis of rejection and definition of AMR
Renal biopsies were evaluated by light microscopy and immuno-
fluoresce. Electron microscopic examination was performed when
glomerular pathology was suspected. The histopathological features
and the classification of rejection were reported according to Banff
2005 updates. We required the simultaneous presence of diffuse
linear C4d deposition in the peritubular capillaries, and presence of
DSA, and morphological evidence of graft injury to diagnose AMR.
Severe intimal arteritis, glomerulitis, capillaritis, and fibrinoid
vascular necrosis and thrombosis were features of AMR.
Staining for C4d in the biopsies was performed on snap-frozen
portion of the biopsy by indirect immunofluorescence technique
using monoclonal antibody to C4d (Biogenesis, Kidlington, UK) at
a dilution of 1:75. In the rare event that snap-frozen tissue of the
kidney biopsy is not available, C4d staining was performed on a
paraffin section using a polyclonal C4d antibody (1:50; American
Research Products, Waltham, MA).
Statistical analysis
Patients were categorized into one of the four following groups
based on presence and type of DSA: no DSA (those without any
detectable DSA); DQ-only (those with only a DQ DSA); nonDQ
(those with DSA directed against an HLA-A, -B, and -DR, but
without a DQ DSA), and DQþ nonDQ DSA (those with DSA
against HLA-A, -B, and/or -DR, as well as against DQ). Baseline
categorical and continuous variables were compared among groups
using 2 and one-way analysis of variance tests, respectively. For
Tables 1 and 2, outcomes were compared between individual groups
using 2 and t-tests for categorical (gender, ethnicity, retransplant status,
induction agent, and rejection) and continuous variables (age, PRA,
creatinine, and time to rejection), respectively. Differences in immu-
nosuppressant dosages and levels (Supplementary Table S1 online)
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were detected using analysis of variance testing, with subsequent
inter-group comparisons made by t-tests. Graft survival, defined as
freedom from the return to dialysis or patient death, was computed
using the Kaplan–Meier method and compared using the log-rank
test.
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